skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections

Review

(2681) Views  (815) Full article downloads

Authors: Dionissios Neofytos, Edina Avdic, Anna-Pelagia Magiorakos

Published Date April 2010 Volume 2010:2 Pages 27 - 38
DOI: http://dx.doi.org/10.2147/DHPS.S6321

Dionissios Neofytos1, Edina Avdic2, Anna-Pelagia Magiorakos3

1Transplant and Oncology Infectious Disease Program, The Johns Hopkins University School of Medicine, Division of Infectious Diseases, 2Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, USA; 3Scientific Advice Unit, European Centre for Disease Prevention and Control, Stockholm, Sweden

Abstract: There has been an increase in the number of patients susceptible to invasive fungal infections (IFIs) leading to a greater need for effective, well tolerated, and easily administered antifungal agents. The advent of triazoles has revolutionized the care of patients requiring treatment or prophylaxis for IFIs. However, triazoles have been associated with a number of adverse events and significant drug–drug interactions. While commonly used, physicians and patients should be aware of the distinct properties of these agents in order to ensure that patients are optimally treated with the least amount of toxicity possible. Clinicians should have a full understanding of the basic pharmacokinetics, absorption, and bioavailability of triazoles. Moreover, knowledge of the drug–drug interactions and potential toxicities of each agent is critical prior to administering a triazole. Careful history taking, thorough review of the patient’s medication list, and detailed discussion with the patients and their families about the efficacy, safety, and tolerability of these agents should be performed. Clinicians treating patients with triazoles should closely follow them, monitor pertinent laboratory tests, and consider measuring drug levels as needed. This article will review the basic pharmacokinetic properties and most frequently encountered adverse events and pitfalls associated with triazoles in clinical practice.

Keywords: triazoles, fluconazole, voriconazole, posaconazole, itraconazole, review, invasive fungal infections, adverse events, drug–drug interactions








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Health literacy and health seeking behavior among older men in a middle-income nation
Development of indicators for identifying adverse drug events in an Indian tertiary care teaching hospital
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Improving health outcomes with better patient understanding and education
Confidentiality of the medical records of HIV-positive patients in the United Kingdom – a medicolegal and ethical perspective
Clinical update on the use of biomarkers of airway inflammation in the management of asthma
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Emerging patient safety issues under health care reform: follow-on biologics and immunogenicity
Ethical principles for project collaboration between academic professionals or institutions and the biomedical industry
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio